| 000 | 01806nam a2200361 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223025926.0 | ||
| 008 | 090915s2009 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.07.M.Sc.2009.No.S | ||
| 100 | 0 | _aNoha Kamal Abdelmoamen | |
| 245 | 1 | 0 |
_aSignificance of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and patients with hepatocellular carcinoma / _cNoha Kamal Abdelmoamen ; Supervised Hebat Allah Mohamed Sharaf Eldeen, Azza Saleh Radwan , Asmaa Ismail Ahmed |
| 246 | 1 | 5 | _aاهمية تركيز الاندوجلين (CD 105) فى مصل الدم فى مرضى تليف الكبد ومرضى اورام الكبد |
| 260 |
_aCairo : _bNoha Kamal Abdelmoamen , _c2009 |
||
| 300 |
_a113P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology | ||
| 520 | _aAim of the work:This study tries to evaluate the role of serum endoglin as a non invasive biomarker in diagnosis of liver cirrhosis and hepatocellular carcinoma. Conclusion:Serum endoglin has the potential to be a novel complementray biomarker for assessment of the risk of the HCC development in the cirrhotic patients | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAlpha fetoprotein | |
| 653 | 4 | _aEndoglin | |
| 653 | 4 | _aLiver cirrhosis and hepatocellular carcinoma | |
| 700 | 0 |
_aAsmaa Ismail Ahmed , _eSupervisor |
|
| 700 | 0 |
_aAzza Saleh Radwan , _eSupervisor |
|
| 700 | 0 |
_aHebat Allah Mohamed Sharaf Eldeen, _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 902 | _a1 | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c23692 _d23692 |
||